1 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
59PubMed Papers
16Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
negative regulation of proteasomal protein catabolic processnucleusnucleoplasmnegative regulation of protein bindingneoplasmosteoporosisarthritiscoronary atherosclerosis
Based on limited published evidence, PSME3IP1 (also known as NIP30) promotes association of the proteasome activator PSME3 with the 20S proteasome while inhibiting PSME3-mediated substrate degradation by regulating substrate diffusion into the catalytic chamber 1. It also inhibits PSME3-COIL interaction and suppresses PSME3 accumulation in Cajal bodies while positively regulating Cajal body number. PSME3IP1 functions as a negative regulator of proteasomal protein catabolic processes and protein binding, localizing to the nucleoplasm and nucleus with roles in mRNA splicing.
1
NIP30 (PSME3IP1) inhibits REGγ-proteasome activity through serine phosphorylation and regulates chemotherapy sensitivity in p53-deficient tumor cells
PMID: 32764536⚠Limited data available — This gene has 1 indexed publication. Summary and analysis may be incomplete.
coronary atherosclerosisOpen Targets
Alzheimer diseaseOpen Targets
depressive disorderOpen Targets
muscle atrophyOpen Targets
squamous cell carcinomaOpen Targets
viral diseaseOpen Targets
cervical cancerOpen Targets
esophageal cancerOpen Targets
gastric cancerOpen Targets
glioma susceptibility 1Open Targets
ovarian serous cystadenocarcinomaOpen Targets
No pathogenic variants reported on ClinVar for this gene.